134
Participants
Start Date
December 7, 2015
Primary Completion Date
November 10, 2022
Study Completion Date
November 10, 2022
RO6874281
RO6874281 will be administered as per the schedule specified under arm description.
Trastuzumab
Trastuzumab will be administered as per the schedule specified under arm description.
Cetuximab
Cetuximab will be administered as per the schedule specified under arm description.
Rigshospitalet; Onkologisk Klinik, København Ø
UZ Antwerpen, Edegem
Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo, Milan
Istituto Europeo di Oncologia; Svil. Nuovi Farmaci per Terapie Innovative, Milan
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck, Milan
Centre Georges Francois Leclerc, Dijon
Ospedale Policlinico S. Matteo; Phase I Clinical Trial Unit and Experimental Therapy, Pavia
Clinica Universitaria de Navarra, Pamplona
Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse
Institut Bergonie; Oncologie, Bordeaux
The Ohio State University, Columbus
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola
Washington University; Division of Oncology, St Louis
Centre Leon Berard, Lyon
Banner MD Anderson Cancer Center, Greeley
University of Arizona Cancer Center, Tucson
UCSD - Moores Cancer Center, La Jolla
Institut Gustave Roussy; Sitep, Villejuif
Juravinski Cancer Clinic; Department of Oncology, Hamilton
Princess Margaret Cancer Center, Toronto
Antoni Van Leeuwenhoek Ziekenhuis; Gastro-Enterologie, Amsterdam
Erasmus MC, Rotterdam
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Leicester Royal Infirmary, Leicester
Guys and St Thomas NHS Foundation Trust, Guys Hospital, London
Christie Hospital, Manchester
Hoffmann-La Roche
INDUSTRY